Clinical Trial

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-30
Trial Details
NCT Number NCT07318324
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Verastem, Inc.
Conditions Phase IB, Avutometinib, RAS Pathway, Endometrial
Enrollment 31 participants
Start Date 2026-05-13
Primary Completion 2028-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29